

Cell Line Data Sheet for LA-N-6

Disease: Neuroblastoma
Phase of Therapy: Post-Chemotherapy (Progressive Disease)
Treatment: 5 cycles of cyclophosphamide and doxorubicin
Disease Stage: 4
Gender: Male
Age at diagnosis: 60 months
Race: N/A
Age at sample collection: N/A
Source of Culture: Bone Marrow
Primary Tumor Site: N/A
Date Established: N/A

MYCN Patient: Non-Amplified
MYCN Cell line: N/A
TH mRNA: Positive
p53 functionality: Functioning
Telomere Mechanism: N/A
ALK: D1091N

IC90 (DIMSCAN*): CBDCA (µg/ml) CDDP (µg/ml) DOX (ng/ml) ETOP (ng/ml) L-PAM (µg/ml)
 *see reference 4 8.6 1.5 113.4 27,339 15.4
 CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
 5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
 Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 150 hours
Growth Properties: Teardrop-shaped cells with processes, adherent, grow mostly in clusters

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes:

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



Cell Line Data Sheet for LA-N-6

References:

1. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds C P: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. *Cancer Res.* 61:6185-6193, 2001. PubMed ID: 11507071
<https://cancerres.aacrjournals.org/content/61/16/6185.long>
2. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. *Prog Clin Biol Res.* 271:291-306, 1988. PubMed ID: 3406003
<https://pubmed.ncbi.nlm.nih.gov/3406003/>
3. Wada RK, Seeger RC, Brodeur GM, Rayner SA, Tomayko MM, Reynolds CP: N-myc expression in human neuroblastoma cell lines without N-myc gene amplification, *Cancer.* 72:3346-3354, 1993. PubMed ID: 8242562
<https://pubmed.ncbi.nlm.nih.gov/8242562/>
4. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. *Cancer Research.* 58:5396-5405, 1998. PubMed ID: 9850071
<https://cancerres.aacrjournals.org/content/58/23/5396.long>
5. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of Protein Gene Product 9.5 and Tyrosine Hydroxylase in Childhood Small Round Cell Tumors. *Clin Cancer Res.* 6, 551-558, 2000. PubMed ID: 10690538
<https://clincancerres.aacrjournals.org/content/6/2/551.long>
6. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. *Cancer Chemoth Pharm.* 45: 1-8, 2000. PubMed ID: 10647494
<https://link.springer.com/article/10.1007%2FPL00006736>
7. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. *Cancer Res.* 61, 679-686, 2001. PubMed ID: 11212268
<https://cancerres.aacrjournals.org/content/61/2/679.long>
8. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. *J Natl Cancer I.* 99: 1107-19, 2007. PubMed ID: 17623797
<https://academic.oup.com/jnci/article/99/14/1107/938992>

9. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer*. 56: 239-249, 2011. PubMed ID: 20922763 (www.PPTPinvitro.org)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>
10. B. Koneru, G. Lopez, A170:E170 A. Farooqi, K. L. Conkrite, T. H. Nguyen, S. J. Macha, A. Modi, J. L. Rokita, E. Urias, A. Hindle, H. Davidson, K. McCoy, J. Nance, V. Yazdani, M. S. Irwin, S. Yang, D. A. Wheeler, J. M. Maris, S. J. Diskin, C. P. Reynolds, Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. *Cancer Res*. 2020;80:2663-2675. PMID 32291317
<https://cancerres.aacrjournals.org/content/80/12/2663.long>
11. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. *Sci Data*. 2017;4:170033. PMID: 28350380
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369315/>

Childhood Cancer Repository
Powered by Alex's Lemonade Stand
COG resource Laboratory
www.cccells.org

2 / 3



Cell Line Data Sheet for LA-N-6

Cell Line Name: LA-N-6

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)

Childhood Cancer Repository
Powered by Alex's Lemonade Stand
COG resource Laboratory

